Abstract:OBJECTIVE:Renal safety risk is currently an important factor that hinders the development of uric acid transporter 1 (URAT1) inhibitors. This study aimed to compare the renal safety and uric acid-lowering efficacy of different URAT1 inhibitors and clarify the association between them.METHODS:A systematic review of published randomized controlled trials on URAT1 inhibitors was conducted to investigate the incidence of renal safety events. A model-based analysis was performed to predict the uric acid-lowering efficacy of representative URAT1 inhibitors.RESULTS:The overall renal safety event incidences of lesinurad, verinurad, dotinurad, SHR4640, and benzbromarone in patients with hyperuricemia were 11.2 % (142/1264), 12.0 % (34/284), 0.5 % (2/421), 2.3 % (5/213), and 1.3 % (5/393), respectively. A semi-mechanistic pharmacokinetic/pharmacodynamic model was used to establish the dose-exposure-effect relationship of lesinurad, verinurad, dotinurad, and SHR4640 with or without the combination of xanthine oxidase inhibitors (XOIs). The efficacy ranking of the intermediate dose of URAT1 inhibitors with once-daily dosing was 2 mg dotinurad > 10 mg verinurad > 5 mg SHR4640 > 400 mg lesinurad. The combination of 80 mg febuxostat and 600 mg allopurinol reduced the 24-h cumulative renal uric acid excretion by 48.4 % and 48.3 %, respectively.CONCLUSION:Uric acid-lowering efficacy is not an independent factor for the renal safety risk of different URAT1 inhibitors, and structural differences could be responsible for the difference. The adverse renal effects of URAT1 inhibitors are dose-dependent, and the combination with high doses of XOIs can significantly reduce the renal safety risk by reducing uric acid excretion by the kidneys.

Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019).

Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020-present)

Urate Transporter URAT1 Inhibitors: a Patent Review (2012 - 2015)

A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications

Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout

[Phylogenetic studies on some Japanese amphibia by mean of immunoelectrophoresis. I. Relationships of some frogs and newt to toad (author's transl)].

A GROUP PARTICIPATION-DEMONSTRATION METHOD OF INTRODUCING PATIENTS TO GROUP PARTICIPATION-DEMONSTRATION METHOD OF INTRODUCING PATIENTS TO GROUP PSYCHOTHERAPY.

Molecular basis of the urate transporter URAT1 inhibition by gout drugs

A System for Discovering Novel Uricosurics Targeting Urate Transporter 1 Based on In Vitro and In Vivo Modeling

Mechanisms of urate transport and uricosuric drugs inhibition in human URAT1

Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout

Structural Insights into the Mechanisms of Urea Permeation and Distinct Inhibition Modes of Urea Transporters

Two distinct mechanisms for ornithine decarboxylase regulation by polyamines in rat hepatoma cells

Molecular mechanisms of uric acid transport by the native human URAT1 and its inhibition by anti-gout drugs

Design, synthesis, and biological evaluation of 3-phenyl substituted pyridine derivatives as potential dual inhibitors of XOR and URAT1

Function of Uric Acid Transporters and Their Inhibitors in Hyperuricaemia

Discovery of a Novel Thienopyrimidine Compound as a Urate Transporter 1 and Glucose Transporter 9 Dual Inhibitor with Improved Efficacy and Favorable Druggability

Systematic Review and Model-Based Analysis to Identify Whether Renal Safety Risks of URAT1 Inhibitors Are Fully Determined by Uric Acid-Lowering Efficacies.

Identification of novel dual inhibitors targeting XOR and URAT1 via multiple virtual screening methods

A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease

New medications in development for the treatment of hyperuricemia of gout